# A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

> **NCT07535112** · PHASE1 · RECRUITING · sponsor: **Bayer** · enrollment: 130 (estimated)

## Conditions studied

- Advanced/Metastatic Colorectal Adenocarcinoma

## Interventions

- **DRUG:** BAY 3771249
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT07535112
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2029-07-27
- **Final completion:** 2030-07-09
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07535112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07535112, "A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07535112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*